Inhalable Drugs Market Size

Inhalable Drugs Market size is estimated at USD 35.8 billion in 2024 and is predicted to reach USD 88.4 billion by the end of 2037, expanding at a CAGR of 7.2% during the forecast period, i.e., 2025-2037. In 2025, the industry size of inhalable drugs is assessed at USD 38.4 billion.

The inhalable medicines are anticipated to exhibit high demand during the forecasted period owing to their ease of use and quick effectiveness. The rising prevalence of chronic respiratory problems such as asthma, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and occupational lung diseases are prime factors fuelling the sales of inhalable drugs.

Research and development focused on the production of advanced medications is set to fuel the sales of modern inhalable drugs in the coming years. For instance, according to the World Health Organization analysis, COPD is the leading cause of death, and around 70% of COPD cases in high-income countries occur due to excessive smoking. Also, asthma is the most common chronic respiratory disease among children. The rising awareness of asthma and treatment is augmenting the demand for inhalers such as bronchodilators and steroids.

Excess intake of psychoactive substances such as alcohol and tobacco coupled with air pollution and chemicals and dust are some of the common factors of chronic respiratory diseases. According to the National Institutes of Health (NIH), alcohol is the major cause of several disorders in underdeveloped and developing countries. For instance, the World Health Organization (WHO) estimates that around 7% of the population across the world above 15 years of age are living with alcohol-related disorders.